Mu Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mu Wang has a total of 30 co-authors. Here are the top co-authors by number of shared publications:
Dawn P. G. Brown
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
3 shared publicationsJinsam You
Indiana University School of Medicine
3 shared publicationsBei Nie
Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN 46202, USA
2 shared publicationsKerry G. Bemis
2 shared publications- Bomie Han
Eli Lilly & Company, Indianapolis, Indiana, USA
1 shared publication Dariusz J. Janecki
Indiana Centers for Applied Protein Sciences (INCAPS), Indianapolis, IN, USA
1 shared publication
Latest Publications
- Open Access
- 29 April 2013
- Published by Wiley in International Journal of Proteomics
- Vol. 2013, 1-2
Advances in Quantitative Mass Spectrometry
- 29 April 2013
- Published by Wiley in International Journal of Proteomics
- Vol. 2013, 1-2
Open AccessAdvances in Quantitative Mass Spectrometry
- 4 November 2011
- Published by Springer Nature
- Vol. 815, 199-225
Mass Spectrometry for Protein Quantification in Biomarker Discovery
Major technological advances have made proteomics an extremely active field for biomarker discovery in recent years due primarily to the development of newer mass spectrometric technologies and the explosion in genomic and protein bioinformatics. This leads to an increased emphasis on larger scale, faster, and more efficient methods for detecting protein biomarkers in human tissues, cells, and biofluids. Most current proteomic methodologies for biomarker discovery, however, are not highly automated and are generally labor-intensive and expensive. More automation and improved software programs capable of handling a large amount of data are essential to reduce the cost of discovery and to increase throughput. In this chapter, we discuss and describe mass spectrometry-based proteomic methods for quantitative protein analysis.
- 4 November 2011
- Published by Springer Nature
- Vol. 815, 199-225
Mass Spectrometry for Protein Quantification in Biomarker Discovery
Major technological advances have made proteomics an extremely active field for biomarker discovery in recent years due primarily to the development of newer mass spectrometric technologies and the explosion in genomic and protein bioinformatics. This leads to an increased emphasis on larger scale, faster, and more efficient methods for detecting protein biomarkers in human tissues, cells, and biofluids. Most current proteomic methodologies for biomarker discovery, however, are not highly automated and are generally labor-intensive and expensive. More automation and improved software programs capable of handling a large amount of data are essential to reduce the cost of discovery and to increase throughput. In this chapter, we discuss and describe mass spectrometry-based proteomic methods for quantitative protein analysis.
- Open Access
- 20 April 2011
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 5 (7-8) , 397-404
Utility of formalin‐fixed, paraffin‐embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis
Purpose: To compare the proteomic profiles of formalin‐fixed, paraffin‐embedded (FFPE) liver biopsy material and matched frozen liver tissue from patients with nonalcoholic steatohepatitis (NASH). Experimental design: A label‐free mass spectrometry‐based approach was used to profile global protein expression in FFPE and frozen liver biopsy specimens from five patients with NASH. Results: Eight hundred and sixty proteins were identified with >75% confidence: 225 common proteins were identified in both the FFPE and frozen tissues, and an additional 142 and 493 proteins were identified in the FFPE and frozen tissues, respectively. Functional analyses revealed a general, nonspecific reduction in the number of proteins identified in FFPE tissue compared with frozen tissue. No bias toward proteins located in any specific subcellular compartments or implicated in any particular biological functions was observed. The relative abundance of several proteins with functions relating to the pathogenesis of NASH (peroxiredoxin‐1, fatty acid binding protein 1, fatty acid synthase, vimentin, catalase, and glutathione S‐transferase A1) was similar in FFPE and frozen liver tissues. Conclusions and clinical relevance: FFPE liver biopsy material from NASH patients can be used for global proteomic analysis and biomarker identification studies, although a universal reduction in the number of identified proteins compared with frozen tissue is likely.
- 20 April 2011
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 5 (7-8) , 397-404
Open AccessUtility of formalin‐fixed, paraffin‐embedded liver biopsy specimens for global proteomic analysis in nonalcoholic steatohepatitis
Purpose: To compare the proteomic profiles of formalin‐fixed, paraffin‐embedded (FFPE) liver biopsy material and matched frozen liver tissue from patients with nonalcoholic steatohepatitis (NASH). Experimental design: A label‐free mass spectrometry‐based approach was used to profile global protein expression in FFPE and frozen liver biopsy specimens from five patients with NASH. Results: Eight hundred and sixty proteins were identified with >75% confidence: 225 common proteins were identified in both the FFPE and frozen tissues, and an additional 142 and 493 proteins were identified in the FFPE and frozen tissues, respectively. Functional analyses revealed a general, nonspecific reduction in the number of proteins identified in FFPE tissue compared with frozen tissue. No bias toward proteins located in any specific subcellular compartments or implicated in any particular biological functions was observed. The relative abundance of several proteins with functions relating to the pathogenesis of NASH (peroxiredoxin‐1, fatty acid binding protein 1, fatty acid synthase, vimentin, catalase, and glutathione S‐transferase A1) was similar in FFPE and frozen liver tissues. Conclusions and clinical relevance: FFPE liver biopsy material from NASH patients can be used for global proteomic analysis and biomarker identification studies, although a universal reduction in the number of identified proteins compared with frozen tissue is likely.
- 18 January 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (7-8) , 700-704
Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells
- 18 January 2010
- Published by Elsevier in Journal of Chromatography B
- Vol. 878 (7-8) , 700-704
Targeted quantitative analysis of superoxide dismutase 1 in cisplatin-sensitive and cisplatin-resistant human ovarian cancer cells
- 12 July 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 63 (4) , 723-730
Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer
Purpose Clinical drug resistance to platinum-based chemotherapy is considered a major impediment in the treatment of human ovarian cancer. Multiple pathways associated with drug resistance have been suggested by many previous studies. Over expression of several key proteins involved in DNA repair, drug transport, redox regulation, and apoptosis has been recently reported by our group using a global quantitative proteomic profiling approach. Superoxide dismutase 1 (SOD1) is one of these proteins consistently over-expressed in cisplatin-resistant ovarian cancer cells as compared to their sensitive counterparts, but its precise role in drug resistance is yet to be defined. Method In the current study, we examined the role of SOD1 in drug resistance by inhibiting its redox activity in cisplatin-resistant ovarian cancer cells using a small-molecule inhibitor, triethylenetetramine (TETA). The effect of TETA was determined by the cell proliferation assay, clonogenic cell survival assay, and SOD1 activity assay. Results The inhibition of the SOD1 activity enhanced the cisplatin sensitivity in the resistant cells supporting the hypothesis that SOD1 is a key determinant of cisplatin resistance and is an exploitable target to overcome cisplatin drug resistance. Conclusion SOD1 plays an important role in cisplatin resistance and modulation of its activity may overcome this resistance and ultimately lead to improved clinical outcomes.
- 12 July 2008
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 63 (4) , 723-730
Targeting superoxide dismutase 1 to overcome cisplatin resistance in human ovarian cancer
Purpose Clinical drug resistance to platinum-based chemotherapy is considered a major impediment in the treatment of human ovarian cancer. Multiple pathways associated with drug resistance have been suggested by many previous studies. Over expression of several key proteins involved in DNA repair, drug transport, redox regulation, and apoptosis has been recently reported by our group using a global quantitative proteomic profiling approach. Superoxide dismutase 1 (SOD1) is one of these proteins consistently over-expressed in cisplatin-resistant ovarian cancer cells as compared to their sensitive counterparts, but its precise role in drug resistance is yet to be defined. Method In the current study, we examined the role of SOD1 in drug resistance by inhibiting its redox activity in cisplatin-resistant ovarian cancer cells using a small-molecule inhibitor, triethylenetetramine (TETA). The effect of TETA was determined by the cell proliferation assay, clonogenic cell survival assay, and SOD1 activity assay. Results The inhibition of the SOD1 activity enhanced the cisplatin sensitivity in the resistant cells supporting the hypothesis that SOD1 is a key determinant of cisplatin resistance and is an exploitable target to overcome cisplatin drug resistance. Conclusion SOD1 plays an important role in cisplatin resistance and modulation of its activity may overcome this resistance and ultimately lead to improved clinical outcomes.
- Open Access
- 25 June 2008
- Published by Oxford University Press (OUP) in Briefings in Functional Genomics and Proteomics
- Vol. 7 (5) , 329-339
Label-free mass spectrometry-based protein quantification technologies in proteomic analysis
Major technological advances have made proteomics an extremely active field for biomarker discovery and validation in recent years. These improvements have lead to an increased emphasis on larger scale, faster and more efficient methods for protein biomarker discoveries in human tissues, cells and biofluids. However, most current proteomic methodologies for biomarker discovery and validation are not highly automated and generally labour intensive and expensive. Improved automation as well as software programs capable of handling a large amount of data are essential in order to reduce the cost of discovery and increase the throughput. In this review, we will discuss and describe the label-free mass spectrometry-based protein quantification technologies and a case study utilizing one of these methods for biomarker discovery.
- 25 June 2008
- Published by Oxford University Press (OUP) in Briefings in Functional Genomics and Proteomics
- Vol. 7 (5) , 329-339
Open AccessLabel-free mass spectrometry-based protein quantification technologies in proteomic analysis
Major technological advances have made proteomics an extremely active field for biomarker discovery and validation in recent years. These improvements have lead to an increased emphasis on larger scale, faster and more efficient methods for protein biomarker discoveries in human tissues, cells and biofluids. However, most current proteomic methodologies for biomarker discovery and validation are not highly automated and generally labour intensive and expensive. Improved automation as well as software programs capable of handling a large amount of data are essential in order to reduce the cost of discovery and increase the throughput. In this review, we will discuss and describe the label-free mass spectrometry-based protein quantification technologies and a case study utilizing one of these methods for biomarker discovery.
- Open Access
- 7 March 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (3) , 246-263
Searching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method
Platinum‐based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum‐based chemotherapy remain unclear. In this study, we applied an LC/MS‐based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780‐CP (cisplatin‐sensitive/cisplatin‐resistant) and 2008/2008‐C13*5.25 (cisplatin‐sensitive/cisplatin‐resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large‐scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.
- 7 March 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (3) , 246-263
Open AccessSearching for potential biomarkers of cisplatin resistance in human ovarian cancer using a label‐free LC/MS‐based protein quantification method
Platinum‐based chemotherapy, such as cisplatin, is the primary treatment for ovarian cancer. However, drug resistance has become a major impediment to the successful treatment of ovarian cancer. To date, the molecular mechanisms of resistance to platinum‐based chemotherapy remain unclear. In this study, we applied an LC/MS‐based protein quantification method to examine the global protein expression of two pairs of ovarian cancer cell lines, A2780/A2780‐CP (cisplatin‐sensitive/cisplatin‐resistant) and 2008/2008‐C13*5.25 (cisplatin‐sensitive/cisplatin‐resistant). We identified and quantified over 2000 proteins from these cell lines and 760 proteins showed significant expression changes with a false discovery rate of less than 5% between paired groups. Based on the results we obtained, we suggest several potential pathways that may be involved in cisplatin resistance in human ovarian cancer. This study provides not only a new proteomic platform for large‐scale quantitative protein analysis, but also important information for discovery of potential biomarkers of cisplatin resistance in ovarian cancer. Furthermore, these results may be clinically relevant for diagnostics, prognostics, and therapeutic improvement for ovarian cancer treatment.
- 11 January 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (1) , 18-31
A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells
Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre‐fractionation and high‐resolution 2‐DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty‐nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine‐sensitive) and SKVLB (vinblastine‐resistant) cell lines. These proteins include membrane‐associated, chromatin remodeling, cytoskeletal, and microtubule‐associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.
- 11 January 2007
- Published by Wiley in Proteomics – Clinical Applications
- Vol. 1 (1) , 18-31
A comparative proteomic study to characterize the vinblastine resistance in human ovarian cancer cells
Drug resistance is a major impediment to the successful treatment of human cancers, including ovarian cancer. Vinblastine (VLB), an antimicrotubule agent, is one of the chemotherapeutic drugs that exhibit resistance in ovarian cancer patients. To determine the protein factors that are involved in vinblastine resistance in human ovarian cancer cells, a combination of sample pre‐fractionation and high‐resolution 2‐DE proteomic analysis was performed. Approximately 1200 proteins were detected and quantitatively compared in both nuclear/membrane and cytosolic fractions. Sixty‐nine proteins from the nuclear/membrane fraction showed altered expression levels, whereas 59 were altered in the cytosolic fraction between SKOV3 (vinblastine‐sensitive) and SKVLB (vinblastine‐resistant) cell lines. These proteins include membrane‐associated, chromatin remodeling, cytoskeletal, and microtubule‐associated proteins as well as others that regulate signal transduction. This study not only demonstrates a novel understanding of the mechanism of drug resistance but also provides a valuable resource for future studies on drug resistance to vinblastine. In addition, it also represents a good example of how to increase the protein dynamic range and reduce sample complexity using currently available tools.